| 18 April 2018

New Team Member at Retina International

http://www.retina-international.org/

Retina International is delighted to announce the appointment of Sarah McLoughlin as Science Communication Officer.

Sarah will be working on the implementation of RI’s communications strategy where she will play a key role in one of the organisations primary objectives: delivery of the latest information on relevant developments in research and innovation to members and stakeholders.


| 06 April 2018

Retina International Supports World Health Day - April 7, 2018

http://www.retina-international.org/

On World Health Day 2018, April 7th, the World Health Organization marks its 70th anniversary. Over the past seven decades, WHO has spearheaded efforts to rid the world of diseases like smallpox and to fight against deadly habits like tobacco use.

In 2018 World Health Day is dedicated to one of WHO’s founding principles:

 “The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, and political belief, economic or social condition.”


| 06 April 2018

ERN-EYE Annual General Meeting - Tallinn

The ERN-EYE organized its third meeting on March 26th to 27th in Tallinn, Estonia. The Annual General Meeting was attended by 60 people from Health Care Providers (HCP) from the 13 member countries in the network, as well as invited speakers.


| 13 February 2018

Foundation Fighting Blindness and ProQR enter into partnership for Usher's Type 2A

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12

Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.


| 04 January 2018

Spark Therapeutics INC announce models of patient access to LUXTURNA

On Wednesday January 3rd 2018,  Spark Therapeutics INC announced a series of payment models designed to help the process of patient access to its new gene therapy LUXTURNA in the United States, which is the only country where the once in a lifetime therapy is currently approved.  The company also announced the cost of the treatment.


| 11 October 2017

Study shows -Avoidable Blindness -Set to Increase in Future

On World Sight Day, eye care organisations around the world take note of new data that shows that global eye care efforts are at serious risk of being overwhelmed—unless we act now.

New data published in the Lancet Global Health shows that decades of declining “avoidable blindness”—those with uncorrected refractive errors and cataract—is plateauing, and is projected to increase between 2015 and 2050.


| 24 September 2017

AMD Week 2017

AMD (Age-related Macular Degeneration) is a condition that affects central vision and is associated with aging. It is important to note however that deteriorating vision is not an inevitable part of the aging process but the result of a particular condition that can, when diagnosed early enough be successfully treated.

In the over 50s, AMD is the leading cause of sight loss.


| 25 July 2017

Members News: 4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding for inherited retinal degenerations (IRD) and dry age-related macular degeneration (AMD), today announced a partnership to develop intravitreal gene therapeutics for patients with these blinding conditions using 4DMT-proprietary AAV vectors.

Join Our Mailing List